Through our venture philanthropy model, we provide early stage funding to companies to develop breakthrough drugs for adults and children with cystic fibrosis.
Site Search
Learn about our focus for 2020-2024 as we advance our path to a cure, meet emerging challenges in care, and explore new ways to partner with and support the CF community.
Engaging with biotechnology and pharmaceutical companies is essential to reaching our goal of a cure for all people with cystic fibrosis. These principles and standards for Industry interactions safeguard our independence, objectivity, and ability to make decisions that are in the best interest of people with CF.
Today, Vertex Pharmaceuticals Inc. released the initial Phase 3 clinical trial data for one of two next-generation, triple-combination modulators currently being tested.
A new drug intended to make it easier to clear mucus from the lungs of people with cystic fibrosis showed promising results in a Phase 2 clinical trial. The drug, called SPX-101, blocks the overactive sodium channels that line CF lung cells.